Description
Background information
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), also known as novel coronavirus 2019-nCoV, causes fever, severe respiratory illness, and can lead to life-threatening pneumonia. The first cases of this disease, termed COVID-19 for coronavirus disease 2019, have been detected in December 2019 in Wuhan, China.
Applications
The MACS GMP PepTivator® SARS-CoV-2 Select can be used for a variety of applications, for example, in vitro stimulation of SARS-CoV-2-specific CD4+ and CD8+ T cells for the enrichment of IFN-gamma–secreting T cells using the CliniMACS® Cytokine Capture System (IFN-gamma) (# 279-01).3
Quality statement
MACS GMP Products are manufactured and tested under a quality management system (ISO 13485) and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.
Disclaimer
MACS GMP Products are for ex vivo cell processing only, and are not intended for human in vivo applications. For regulatory status in the USA, please contact your local representative.
Overview
The MACS GMP PepTivator® SARS-CoV-2 Select is a peptide pool that consists of 88 lyophilized peptides of 9–22 aa in length. 63 of these peptides are MHC class I and 25 peptides are MHC class II–restricted. The peptides originate from structural proteins (S, M, N, E) as well as non-structural proteins.
The peptides are restricted for the following HLA-molecules: HLA-A*01, A*02, A*03, A*11, A*24, A*29, A*30, A*31, A*68, B*07, B*08, B*15, B*27, B*35, B*40, B*44, B*54, B*58, C*07, DRB1*01, DRB1*03, DRB1*04, DRB1*07, DRB1*11, DRB1*15.
It has been developed for efficient in vitro stimulation and subsequent isolation of SARS-CoV-2–specific CD4+ and CD8+ T cells.
